# Prescribing Complexities: A Patient Story Related to Seizure History and the Changing Therapeutic Landscape of Alzheimer’s Disease

## TL;DR

This paper discusses the challenges of prescribing new Alzheimer’s medications to patients with a history of seizures.

## Contribution

It presents a case study emphasizing the need for careful risk-benefit assessments in patients with seizure history.

## Key findings

- Patients with a history of seizures may face unique risks with anti-amyloid Alzheimer’s medications.
- The case highlights the importance of considering seizure history in treatment decisions for Alzheimer’s.
- Risk-benefit assessments are crucial for personalized treatment in this patient group.

## Abstract

The therapeutic landscape of Alzheimer’s disease (AD) is rapidly changing. Disease-modifying medications for AD that target amyloid-beta (Aß) deposits in the brain have been approved by the Food and Drug Administration (FDA) in recent years. However, there remain many questions about which patients are most appropriate for these medications. One group in particular with unique considerations includes older adults with a prior history of seizures. AD and seizures represent an important, bidirectional relationship. This case report presents a patient story that highlights the importance of discussions around seizure history in consideration of anti-amyloid medications and the importance of risk-benefit assessments when considering anti-amyloid therapeutics for patients with AD.